Longitude Capital

Longitude Capital is a healthcare-focused venture capital firm that invests across biotechnology, medical technology, and health solutions sectors. Established in 2006, the firm seeks out transformative companies that can improve clinical outcomes, enhance quality of life, and drive healthcare efficiencies. They invest across various stages, from startups to growth companies, with a unique focus on areas like oncology, neurodegenerative diseases, aging, and cardiovascular solutions. Longitude's approach is flexible, allowing them to invest in early clinical-stage companies, spin-outs, and even publicly traded firms. The firm is known for its involvement in special situations, including recapitalizations and PIPEs (Private Investment in Public Equity). They have a proven track record with successful IPOs and acquisitions, such as Aimmune Therapeutics, KaNDy Therapeutics, and Axonics Modulation Technologies. With $585 million raised in its latest fund (LVP4), Longitude Capital's strategy remains rooted in long-term value creation, bolstered by robust internal research teams. Their offices are located in Menlo Park, Greenwich, and Boston, and they continue to partner with both emerging and established healthcare innovators.